Huntleigh Advisors Inc. Increases Stock Holdings in Natera, Inc. $NTRA

Huntleigh Advisors Inc. lifted its stake in Natera, Inc. (NASDAQ:NTRA) by 3.8% in the second quarter, Holdings Channel.com reports. The firm owned 10,407 shares of the medical research company’s stock after buying an additional 380 shares during the period. Huntleigh Advisors Inc.’s holdings in Natera were worth $1,758,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Chevy Chase Trust Holdings LLC boosted its holdings in shares of Natera by 5.4% in the 2nd quarter. Chevy Chase Trust Holdings LLC now owns 596,939 shares of the medical research company’s stock worth $100,847,000 after purchasing an additional 30,390 shares during the period. Nordea Investment Management AB boosted its holdings in Natera by 7.3% during the 2nd quarter. Nordea Investment Management AB now owns 10,152 shares of the medical research company’s stock valued at $1,711,000 after acquiring an additional 687 shares during the period. WCM Investment Management LLC boosted its holdings in Natera by 8.2% during the 2nd quarter. WCM Investment Management LLC now owns 6,465 shares of the medical research company’s stock valued at $1,086,000 after acquiring an additional 490 shares during the period. Ritholtz Wealth Management purchased a new position in Natera during the 2nd quarter valued at $296,000. Finally, Harbour Investments Inc. boosted its holdings in Natera by 120.9% during the 2nd quarter. Harbour Investments Inc. now owns 2,171 shares of the medical research company’s stock valued at $367,000 after acquiring an additional 1,188 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on NTRA shares. Royal Bank Of Canada set a $268.00 price objective on Natera and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Cowen restated a “buy” rating on shares of Natera in a report on Friday, August 8th. Stephens restated an “overweight” rating and set a $183.00 price objective on shares of Natera in a report on Friday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a report on Wednesday, October 8th. Finally, Morgan Stanley restated an “overweight” rating and set a $195.00 price objective on shares of Natera in a report on Sunday, August 10th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $196.81.

Natera Stock Up 0.6%

Shares of NASDAQ NTRA opened at $181.69 on Friday. The business has a fifty day simple moving average of $168.19 and a two-hundred day simple moving average of $158.35. The firm has a market cap of $24.94 billion, a PE ratio of -95.13 and a beta of 1.74. Natera, Inc. has a twelve month low of $117.27 and a twelve month high of $187.34.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). The firm had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company’s revenue for the quarter was up 32.2% on a year-over-year basis. During the same period last year, the firm earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. On average, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Michael Burkes Brophy sold 3,045 shares of the business’s stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total value of $418,383.00. Following the completion of the transaction, the chief financial officer directly owned 65,430 shares of the company’s stock, valued at approximately $8,990,082. The trade was a 4.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Steven Leonard Chapman sold 14,083 shares of the business’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $160.00, for a total value of $2,253,280.00. Following the completion of the transaction, the chief executive officer directly owned 154,072 shares of the company’s stock, valued at approximately $24,651,520. The trade was a 8.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,464 shares of company stock valued at $10,963,125. 5.63% of the stock is currently owned by insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.